CMAC’s vision has been developed through close collaboration with industry and the support of its Tier 1 partners, AstraZeneca, Bayer, GlaxoSmithKline, Lilly, Novartis, Pfizer, Roche and Takeda and a wide range of technology companies.
CMAC has already saved companies £20M p.a, leveraged a £150M funding portfolio, and currently comprises more than 130 staff and researchers, including academics, post docs, 50 PhD students and an experienced support team.
Underpinning CMAC’s success is the ability to solve industry relevant problems and drive technology development. The industry partners collaborate with the CMAC academic community to steer the research programme and facilitate translation to industry, operating to a higher Technology Readiness Level (TRL).
The demand-led manufacturing research scope has been developed through close collaboration with a wide range of technology companies and the support of its Tier 1 partners:
AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Roche, Takeda
The CMAC partners support the Future Manufacturing Research Hub and Doctoral Training Centre, helping shape research to ultimately transform medicines development and manufacture. As such, activities are aligned across the innovation landscape, spanning multiple TRLs to address industry needs.
For further information on CMAC industry engagement please refer to the CMAC Strategy.
For further information please contact:
Massimo Bresciani, Industry Director
Rebekah Russell, Tier 1 Co-ordinator
Dr Claire MacDonald, Tier 1 Key Account Manager
Dr Iyke Onyemelukwe, Technical Translation Manager
